Monopar Therapeutics Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
Monopar Therapeutics Inc. (MNPR) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents of $5.00 million as of 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Notes › Business Combination, Recognized Asset Acquired, Asset › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents · last filed 2019-02-26
- 2018-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $5.00M.
- 2017-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $5.00M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents |
|---|---|
| 2018-12-31 | $5.00M 10-K · filed 2019-02-26 |
| 2017-12-31 | $5.00M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |